Evaluation and treatment of the human immunodeficiency virus-1-exposed infant
Author(s) -
Donna C. Futterman,
Lisa M. Henry-Reid,
Jennifer S. Read,
Diane W. Wara
Publication year - 2004
Publication title -
paediatrics and child health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.55
H-Index - 43
eISSN - 1918-1485
pISSN - 1205-7088
DOI - 10.1093/pch/9.6.409
Subject(s) - chemoprophylaxis , medicine , human immunodeficiency virus (hiv) , transmission (telecommunications) , pneumonia , pediatrics , antiretroviral treatment , pneumocystis pneumonia , immunology , antiretroviral therapy , intensive care medicine , viral load , pneumocystis jirovecii , electrical engineering , engineering
In developed countries, care and treatment are available for pregnant women and infants that can decrease the rate of perinatal human immunodeficiency virus type 1 (HIV-1) infection to 2% or less. The paediatrician has a key role in the prevention of mother-to-child transmission of HIV-1 by identifying HIV-exposed infants whose mothers' HIV infection was not diagnosed before delivery, prescribing antiretroviral prophylaxis for these infants to decrease the risk of acquiring HIV-1 infection, and promoting avoidance of HIV-1 transmission through human milk. In addition, the paediatrician can provide care for HIV-exposed infants by monitoring them for early determination of HIV-1 infection status and for possible short- and long-term toxicities of antiretroviral exposure, providing chemoprophylaxis for Pneumocystis pneumonia, and supporting families living with HIV-1 infection by providing counselling to parents or caregivers.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom